NEW YORK (GenomeWeb News) – Horizon Discovery today said that it has inked a research collaboration with the University of Liverpool to use the firm's tools to identify and validate cancer drug targets and biomarkers for personalized cancer therapy and diagnostics.

The partners will utilize Horizon's X-Man cell lines and have access to the firm's panel of over 150 genetically-defined isogenic disease models, said Horizon. The company will work with Michael Clague of the University of Liverpool to identify unique protein biomarker signatures.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.